Xiaowei Xu

faculty photo
Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia PA
Member, Abramson Cancer Center
Department: Pathology and Laboratory Medicine

Contact information
Hospital of University of Pennsylvania
Dept. of Pathology and Laboratory Medicine
6 Founders Pavilion
Philadelphia, PA 19104-4283
Office: 215-662-6503
Fax: 215-349-5910
Education:
MD (Medicine)
Fudan University School of Medicine, Shanghai, China, 1992.
PhD (Pharmacology)
Wake Forest University School of Medicine, Winston-Salem, NC, 1996.
Post-Graduate Training
Postdoctoral Fellowship, Department of Physiology and Pharmacology, Dr. William Sonntag's Lab, Wake Forest University, Winston Salem, NC, 1996-1997.
Resident in Anatomic and Clinical Pathology, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, 1997-2001.
Postdoctoral Fellowship, Department of Dermatology, Dr. George Cotsarelis' Lab, University of Pennsylvania, Philadelphia, PA, 1999-2001.
Clinical Fellowship in Dermatopathology, Harvard Medical School, Boston, MA, 2001-2002.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Skin stem cells and melanoma

Description of Itmat Expertise

Dr. Xu's lab studies skin adult stem cell, melanocyte and melanoma biology with aims to effective therapies for vitiligo, melasma, melanoma and other skin conditions.

Selected Publications

Fane ME, Chhabra Y, Alicea GM, Maranto DA, Douglass SM, Webster MR, Rebecca VW, Marino GE, Almeida F, Ecker BL, Zabransky DJ, Hüser L, Beer T, Tang HY, Kossenkov A, Herlyn M, Speicher DW, Xu W, Xu X, Jaffee EM, Aguirre-Ghiso JA, Weeraratna AT.: Stromal changes in the aged lung induce an emergence from melanoma dormancy. Nature 606(7913): 396-405, 2022.

Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, Xia H, Man Q, Zhong W, Antelo LF, Wu B, Xiong X, Liu X, Guan L, Li T, Liu S, Yang R, Lu Y, Dong L, McGettigan S, Somasundaram R,Radhakrishnan R, Mills G, Lu Y, Kim J, Chen YH, Dong H, Zhao Y, Karakousis GC, Gangadhar TC, Schuchter LM, Herlyn M, Wherry EJ, Xu X,* Guo W*. * indicates co-corresponding authors : Exosomal PD-L1 Mediates Tumor Immunosuppression and is Associated with Patient Response to anti-PD-1 Immunotherapy. Nature 560(7718): 382-386, 2018.

Lu H, Liu S, Zhang G, Bin Wu, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M*, Xu X*, Guo W*. *Herlyn, Xu and Guo are co-corresponding authors.: PAK Signaling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAFmutant Melanomas. Nature 550(7674): 133-136, 2017

Wang H, Chen H, Liu S, Zhang J, Lu H, Somasundaram R, Choi R, Zhang G, Ou L, Scholler J, Tian S, Dong L, Yeye G, Huang L, Connelly T, Li L, Huang A, Mitchell TC, Fan Y, June CH, Mills GB, Guo W, Herlyn M, Xu X. : Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function. J Immunother Cancer. 9(12): e003339, 2021.

Ou L, Wang H, Liu Q, Zhang J, Lu H, Luo L, Shi C, Lin S, Dong L, Guo Y, Huang L, Zhu J, Yin X, Huang AC, Karakousis G, Schuchter L, Amaravadi R, Zheng C, Fan Y, Guo W, Xu X. : Dichotomous and stable gamma delta T-cell number and function in healthy individuals. J Immunother Cancer 9(5): e002274, 2021.

Menzies AM, Amaria RN, Rozeman EA, Huang AC, Tetzlaff MT, van de Wiel BA, Lo S, Tarhini AA, Burton EM, Pennington TE, Saw RPM, Xu X, Karakousis GC, Ascierto PA, Spillane AJ, van Akkooi ACJ, Davies MA, Mitchell TC, Tawbi HA, Scolyer RA, Wargo JA, Blank CU, Long GV.: Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med 27(2): 301-309, 2021

Liu S, Zhang G, Guo J, Chen X, Lei J, Ze K, Dong L, Dai X, Song D, Ecker B, Yang R, Feltcher C, Peng K, Feng C, Chen H, Lee RX, Kerestes H, Niu J, Kumar S, Xu W, Zhang J, Wei Z, Martin JS, Liu X, Mills G, Lu Y, Guo W, Weeraratna A, Herlyn M, Wei W, Lee FS, Xu X : Loss of Phd2 Cooperates with BRAFV600E to Drive Melanomagenesis. Nat Commun. 9(1): 5426, 2018

Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya AA, Wubbenhorst B, Dorfman L, D'Andrea K, Wenz BM, Liu S, Chilukuri L, Kozlov A, Carberry M, Giles L, Kier MW, Quagliarello F, McGettigan S, Kreider K, Annamalai L, Zhao Q, Mogg R, Xu W, Blumenschein WM, Yearley JH, Linette GP, Amaravadi RK, Schuchter LM, Herati RS, Bengsch B, Nathanson KL, Farwell MD, Karakousis GC, Wherry EJ, Mitchell TC.: A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 25(3): 454-61, 2019

Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, Werner MT, Huang AC, Alexander KA, Wu JE, Attanasio J, Yan P, George SM, Bengsch B, Staupe RP, Donahue G, Xu W, Amaravadi RK, Xu X, Karakousis GC, Mitchell TC, Schuchter LM, Kaye J, Berger SL, Wherry EJ: TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571(7764): 211-218, 2019.

Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton B, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KYJ, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D’Andrea K, Koehler A, Stumm M, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K: Clinical efficacy of a RAF inhibitor requires comprehensive ERK pathway inhibition in BRAF-mutant melanoma. Nature 467(7315): 596-9, 2010

back to top
Last updated: 10/26/2022
The Trustees of the University of Pennsylvania